New Payer Landscape Insights: BCG-Unresponsive NMIBC Treatment Coverage
January 8, 2026
Our latest analysis reveals key coverage trends for three therapies treating high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC):
Coverage Snapshot (267M+ covered lives analyzed):
- Anktiva leads with 158M covered lives for CIS-only indication
- Adstiladrin: 115M covered lives (CIS-only)
- Keytruda: 113M covered lives (CIS-only)
Key Findings: The CIS-only indication dominates coverage across all three drugs, though we're seeing notable expansion in CIS+Papillary Non-CIS coverage for Adstiladrin and Keytruda. Policy requirements vary significantly by payer, with most aligning to FDA labels while some apply different criteria than NCCN guidelines.
Want the full breakdown on coverage trends, TURBT requirements, and payer-specific policies? Download a sample from the complete Executive Summary Report.
New Payer Landscape Insights: BCG-Unresponsive NMIBC Treatment Coverage
Please submit the form below to view this resource.
Request Access
Please fill out the form below to access our Industry Resources.
By submitting this form, you agree to our use of this information for the purpose of contacting you. For more information, please refer to our privacy policy.